Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D J Straus

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1983
Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV)D J Straus, J Myers, B Koziner, et al.
Leukemia|January 1, 1991
Diffuse large cell lymphoma. Prognostic factors with treatmentD J Straus, G Wong, J Yahalom, et al.
Cancer|April 1, 1993
Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapyJ Baselga, S E Krown, E E Telzak, et al.
Cancer|April 1, 1993
Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized studyJ Yahalom, G Varsos, Z Fuks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious DiseasesD J Straus, J Huang, M A Testa, et al.
Cancer|November 15, 1987
Generalized lymphadenopathy with morphologic features of Castleman's disease in an HIV-positive manD A Lowenthal, D A Filippa, M E Richardson, et al.
Chest|May 16, 2000
Abnormal flow volume loops in patients with intrathoracic Hodgkin's diseaseN J Vander Els, F Sorhage, A M Bach, et al.
Cancer Treatment Reports|March 1, 1981
Combination chemotherapy salvage of heavily pretreated patients with Hodgkin's disease: an analysis of prognostic factors in two chemotherapy trials and the literatureD J Straus, S Passe, B Koziner, et al.
The American Journal of Medicine|February 1, 1987
Non-Hodgkin's lymphomas: characteristics of long-term survivors following conservative treatmentD J Straus, J J Gaynor, P H Leiberman, et al.
Clinical Bulletin|January 1, 1980
The treatment of advanced Hodgkin's disease at Memorial HospitalD J Straus, C W Young, B J Lee, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
Cancer Chemotherapy and Pharmacology|January 1, 1983
Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV)D J Straus, J Myers, B Koziner, et al.
Leukemia|January 1, 1991
Diffuse large cell lymphoma. Prognostic factors with treatmentD J Straus, G Wong, J Yahalom, et al.
Cancer|April 1, 1993
Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapyJ Baselga, S E Krown, E E Telzak, et al.
Cancer|April 1, 1993
Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized studyJ Yahalom, G Varsos, Z Fuks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious DiseasesD J Straus, J Huang, M A Testa, et al.
Cancer|November 15, 1987
Generalized lymphadenopathy with morphologic features of Castleman's disease in an HIV-positive manD A Lowenthal, D A Filippa, M E Richardson, et al.
Chest|May 16, 2000
Abnormal flow volume loops in patients with intrathoracic Hodgkin's diseaseN J Vander Els, F Sorhage, A M Bach, et al.
Cancer Treatment Reports|March 1, 1981
Combination chemotherapy salvage of heavily pretreated patients with Hodgkin's disease: an analysis of prognostic factors in two chemotherapy trials and the literatureD J Straus, S Passe, B Koziner, et al.
The American Journal of Medicine|February 1, 1987
Non-Hodgkin's lymphomas: characteristics of long-term survivors following conservative treatmentD J Straus, J J Gaynor, P H Leiberman, et al.
Clinical Bulletin|January 1, 1980
The treatment of advanced Hodgkin's disease at Memorial HospitalD J Straus, C W Young, B J Lee, et al.
Pageof 9